View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
In the past, few employers in the veterinary profession have chosen to advertise salary details, perhaps because they don't want to open a negotiation with their cards on the table, or perhaps they've been fearful of their existing employees finding out what they're prepared to offer a new candidate.
In the VetSurgeon forums, some employers have also remarked that the job isn't about money, and they wouldn't be interested in a candidate whose search criteria included the salary on offer.
The reality, of course, is that we all have bills to pay, children to feed or mortgages to cover and whilst few if any veterinary surgeons search for a job on the basis of salary alone, it's perfectly reasonable that the salary is part of their deliberations.
More than that, all the indications are that job advertisements which include salary details generate more, better qualified responses. Reed carried out a survey of 1000 jobseekers in 2016, 2/3rds of whom said they would be more likely to apply when a salary is displayed on the advert. Another company, Smart Recruit Online, found back in 2013 that job adverts which included a salary generated 30% more responses that those that didn't.
There are also indications that in the future, Google may start to prioritise jobs advertised with salary information in its search results.
To try and strike a balance between some employers' reluctance to display what they might be prepared to pay and the need for greater transparency, advertisers can now display a 'Minimum Offer' on VetSurgeon Jobs, described to the potential applicant as: "The minimum this employer is prepared to offer someone with the skills and experience needed to fulfil the job requirements. They may or may not be prepared to offer more. They may also be prepared to accept someone with a lower level of qualification or experience for an amount less than displayed."
Alternatively, employers can advertise a 'Pay Range', described to potential applicants as: "The employer expects to pay something within the displayed range, depending on their assessment of the value of the applicant's skills and experience to the practice."
In addition, employers can also display other benefits which are likely to be of more or less value to individual applicants, such as a RCVS fees, association subscriptions, health insurance and CPD allowances.
VetSurgeon.org Editor Arlo Guthrie said: "This is entirely optional, but I do hope as many employers as possible will make good use of this new feature, because all the research and anecdotal evidence suggests it’s what candidates want to hear, and it should lead to a better response. Not to mention how time-saving it is for two people to come to the table with realistic expectations."
I had hoped that the increasing absurdity of the reasons given for the rise might have tipped everyone off to the fact that the story was a spoof.
The idea that the College would ask its members to fund some glitzy, showy, award-winning designer headquarters along the lines of London’s City Hall? C’mon. London City Hall employs 1000 staff, whilst the Royal College employs less than 100. And let's face it, the RCVS has no record of having showy offices. On the contrary, it has managed to operate out of a sardine can now for a great many years. Have you ever been in the lift at Horseferry Road? You need to breathe in.
Or that the College had set aside £6M to recruit and pay 20 veterinary surgeons as short term contracted OVs to help in the event of a no-deal Brexit. Let’s say a flight from Delhi to London costs £500, give or take. Twenty vets. That’s £10,000 to get them here. Let's say they’re here for 6 months. That’s £299,500 per vet. You really think the College is going to ask you to pay more than a quarter of a million pounds to fly in a single vet for 6 months? Or that 20 recruits would solve the predicted OV shortage?
Lastly, the quote, supposedly from an Indian vet, but one with a name that doesn’t really sound like a name (still less an Indian one), but does sound strangely like it may be an anagram of April Fool.
There have been a small number of reports of people being really upset by this story. I guess they must have skim read, or only read the headline.
To them I want to say sorry, I genuinely didn’t mean to upset anyone.
In fact, I thought it might cause some reflection on what good value the RCVS really offers. It maintains the register and thereby your ability to practice, it runs the disciplinary process (an essential component of maintaining public trust), it oversees and sets educational standards, it awards Fellowships, Diplomas and Certificates, it runs the Practice Standards Scheme.
All that, and more for £340 per annum?
Honestly? I think it would be cheap at half the price.
Photo: Truth is that the RCVS has operated out of a sardine can for years.By Rl - Own work, CC BY-SA 3.0, Link
MSD Animal Health has launched an improved on-farm calf-side scour pathogen testing kit for faster diagnosis of the main infectious organisms implicated in a disease outbreak.
According to the company, the new ScourCheck Rapid Programme promises a 10-minute diagnostic turnaround from faecal sample to result, enabling the veterinary practitioner to offer more timely disease management recommendations without having to wait for a laboratory report. The new kits deliver on-farm identification of rotavirus, coronavirus, cryptosporidium and E. coli K99.
Further details on the ScourCheck Rapid Programme are available from MSD Animal Health account managers.
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
Fitzpatrick Referrals has carried out a world-first procedure in which an American Bulldog was fitted with a prosthetic hip and femur with a special in-growth attachment which effectively re-attaches the tendons and muscles to the artificial limb.
The procedure took place after 8 year old Roly was diagnosed with cancer in his rear hind leg earlier this year. It involved a highly complex two-hour operation, during which Dr Noel Fitzpatrick, a neuro-orthopaedic veterinary surgeon, replaced the cancerous femur bone and hip joint with a specially constructed artificial prosthesis, while re-attaching the musculature and realigning the relative position of the joint to restore perfect movement to the dog.
The prosthesis was designed through a collaboration between Professor Gordon Blunn, Head of the Centre for Bio-Medical Engineering at UCL's Institute of Orthopaedics and Musculoskeletal Science; veterinary surgeon Noel Fitzpatrick and Jay Meswania from specialist implant manufacturer OrthoFitz.
Professor Blunn said: "What is significant about the design is the way in which it sandwiches tissue and metal together overlaying the gluteal muscles onto the top of the endoprosthetic femur - alternating tendon, synthetic Dacron mesh, tendon, synthetic Dacron mesh, tendon and finally trabecular metal - which has a honeycomb surface resembling a series of small chambers. In this way, the hope is that the Sharpeys fibres which attach tendons of muscles to the bone will grow into the trabecular metal surface and permanently adhere to it."
"This truly remarkable achievement was made possible through the convergence of biomechanics, biology and surgical innovation," said Noel Fitzpatrick. "We tapped into the evidence provided by the CT and MRI scanners we have in place at the practice, so that the data collected about Roly during clinical diagnosis was used to design and construct an artificial femur which exactly mirrored his original limb. It has been constructed rather like a telescope - one section fitting inside the adjoining section, so that we get maximum flexibility and traction during motion."
Noel added: "Hip replacement is common here. We do more than 50 a year, on animals as small as a cat or a Chihuahua. But this hip replacement was special, and to my knowledge, the first of its kind in the world. It's important though to emphasise that this technology must only be employed when it is in the best interests of the individual patient. It's not enough to be able to do something; it must be done for the right reason in every case without exception. It must be ethically right. It's also important to emphasise that Roly will probably not live for a normal lifetime because bone cancer generally spreads to the lungs over time in spite of chemotherapy. However, this technology is equally applicable for dogs and cats affected by trauma who will likely live longer. My job is to look after my patients as best I can and to be honest with their guardians and give them options. What I do is provide pain free functional quality of life for as long as my patient is alive. That's important and that's special, but the decision must remain with each and every individual animal owner".
According to the team, this development also has potentialy life-changing implications for human patients such as motorcycle accident victims, where a key challenge to recovery may be successfully re-attaching the kneecap tendon onto the top of the tibia in the lower leg, and injured sports players with ruptured repairing ruptured tendons.
Click here to view the x-rays of this case in the VetSurgeon Gallery.
The Disciplinary Committee heard four charges against Dr Schulze Allen.
The first charge related to the original criminal conviction in the County of San Bernardino in California dating from September 2013, where Dr Schulze Allen pleaded guilty to petty theft for which he was fined US $435 and ordered to pay a fee of US $35.
The second charge related to the fact that, on or around 3 December 2013 in a written application for restoration to the Register, Dr Schulze Allen was dishonest in representing that he did not have any cautions or criminal convictions.
The third charge related to the fact that on or around 4 December 2013 in a sworn affidavit before a Notary Public in Riverside, California, he dishonestly and falsely represented that he had, at no time, been convicted of a criminal offence in the UK or elsewhere.
The final charge was that, in an email to the RCVS in June 2016, he dishonestly and falsely represented that he had "no criminal record whatsoever".
Having found Dr Schulze Allen guilty of all four charges the Committee then considered whether the conviction rendered him unfit to practise veterinary surgery and whether the remaining charges amounted to disgraceful conduct in a professional respect.
The Committee noted that the conviction was for a minor matter but had regard to all the evidence before it and considered that as an offence of dishonesty it represented a breach of one of the fundamental tenets of the profession. It further considered that Dr Schulze Allen’s dishonesty toward the College and his completing a legal document which he knew would be relied upon by the College was conduct that fell far short of the standard expected of a member of the profession.
With regard to the final charge, the Committee considered this a "clear attempt to deliberately misrepresent the fact that he had a conviction for a criminal offence." The Committee considered that Dr Schulze Allen’s conduct had been aggravated by the fact that it was protracted and repeated over a period of time.
Ultimately the Committee considered that the conviction rendered Dr Schulze Allen unfit to practise veterinary surgery and the remaining charges amounted to disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "His conduct represented a blatant disregard of the role of the RCVS and the systems that regulate the veterinary profession. The Committee also remained particularly concerned at Dr Schulze Allen’s very limited insight into his conduct."
He added: "In mitigation the Committee noted that this is not a case where harm was caused to any animals or humans. It noted that prior to these matters which are before the Committee that Dr Schulze Allen had an unblemished career and that he had been of good character. In respect of purely personal mitigation the Committee noted that Dr Schulze Allen is the main breadwinner of the family."
However, the Committee considered that Dr Schulze Allen’s conduct had fallen significantly short of standards expected of a veterinary surgeon.
Ian Green concluded: "The Committee considered that the only appropriate sanction is that of removal from the Register. Such a sanction is required to send a clear message to Dr Schulze Allen and to veterinary surgeons of the unacceptability of being dishonest to the RCVS. Such conduct undermines public confidence in the profession and fails to uphold proper standards of conduct and behaviour.
"Accordingly, the Committee has decided that removal from the Register is appropriate and proportionate in this case. The Committee will direct the Registrar to remove the respondent’s name from the Register forthwith."
Dr Schulze Allen has 28 days from the date of the decision to appeal the Committee’s decision.
The Committee’s full findings and decision is available at www.rcvs.org.uk/disciplinary.
The guidelines, launched during WSAVA World Congress 2018 in Singapore, aim to bridge differing perceptions of welfare around the world and help veterinary surgeons and nurses tackle the ethical questions and moral issues which impact welfare.
They also offer guidance to ensure that, in addition to providing physical health advice and therapy to their patients, veterinary surgeons and nurses can advocate for their psychological, social and environmental wellbeing.
Dr Shane Ryan, incoming President of the WSAVA and former Chair of the WSAVA Animal Wellness and Welfare Committee, said: "As veterinarians, our responsibility extends far beyond the physical health of our patients. Animal welfare as a science is a new and rapidly developing discipline and veterinarians need current, evidence-based invformation to enable them to maintain the highest welfare standards and to provide knowledgeable, accurate advice for pet owners and communities.
"Our new Guidelines provide recommendations, checklists and other tools to promote optimal levels of welfare throughout the veterinary visit. They also offer guidance on increasing welfare beyond the doors of the clinic through outreach activities.
"As levels of pet ownership increase in many regions of the world, including Asia, it is essential that veterinarians champion animal welfare and the WSAVA hopes that these new Guidelines will encourage our members to adopt best practice and set the highest standards.
"I would like to thank the members of the Animal Welfare Guidelines team, who worked so hard to create them and, of course, our sponsor, Waltham, whose constant support was instrumental in enabling us to deliver them."
The Animal Welfare Global Guidelines for Companion Animal Practitioners and the Veterinary Team are available for free download at: https://bit.ly/2D3RAoc.
Revozyn RTU, which contains 400 mg/ml Penethamate hydriodide, is the first ready-to-use injectable narrow spectrum Penethamate on the UK market. It can also be used to treat relapses of old infections.
Dechra says that the intramuscular injection works by diffusing through the blood vessels and accumulating in the udder tissue and milk, treating the whole udder effectively. Apparently the new formulation also features an ion trapping mechanism that results in high Benzylpenicillin concentration in milk and udder tissue.
Revozyn RTU comes in a 50ml multi dose vial. It has a 28-day shelf life after first use and has withdrawal periods of four days for milk and 10 days for meat and offal.
Dechra Brand Manager Emma Jennings said: "The treatment and control of mastitis is one of the largest costs to any dairy farmer. It affects productivity and cow welfare and we are delighted to be able to introduce this revolutionary product.
"Revozyn RTU can change the way that clinical and subclinical mastitis in dairy cattle is treated. Its narrow spectrum of activity means that the risk of antibiotic resistance is reduced and there is no need for additional animal handling, thereby saving time and protecting user safety.
“The flexible dosing of Revozyn RTU and 28-day shelf life also make it a cost effective option for farmers".
For more information, visit www.dechra.co.uk.
The range includes:
Fluodrop (the first fluorescein product specifically designed for veterinary use)
Ocryl - an ocular and periocular cleanser that can also be used to reduce and prevent unsightly tear staining
Ocular lubricants (carbomer and hyaluronic acid based)
Clerapliq – a novel molecule to the UK veterinary market that is used to help restore and regenerate the corneal extracellular matrix
The products will be supported with a selection of materials to help vets, nurses and pet owners in the maintenance of corneal health, including diagnosis and treatment guidelines, anatomical guides, posters and client educational and treatment aids to help with compliance.
William Peel MRCVS, product manager at TVM-UK said: "Our Corneal Focus Range is an exciting way to expand on our product portfolio following the successful introduction of our ‘Anti-tox’ range.
"With ‘Anti-tox’ we successfully managed to make vets and nurses lives easier by providing education and materials alongside a great range of products to help when dealing with poisoning cases in practice. We also attempted to make clients more aware of the dangers of poisoning in pets.
"We hope to emulate this approach and success with our Corneal Focus Range – by developing a wealth of materials for vets, nurses and clients to aid them in managing and understanding ophthalmology cases – and by providing quality products."
TVM UK will be showcasing its new products and support services at the London Vet Show (stand P40) this November.
For more information, visit: http://www.tvm-uk.com/
Zoetis has announced the launch of Contacera (meloxicam) 15mg/ml oral suspension, a non-steriodal anti-inflammatory preparation for horses.
According to the company, meloxicam has been shown to hold advantages over Phenylbutazone for the alleviation of musculoskeletal inflammation and pain in horses over six weeks of age1,2,3,4.
Contacera can be mixed with food or syringed directly into the mouth to ensure compliance. It is available in 100ml or 250ml bottles, with a measuring dose syringe and a syringe adaptor. Contacera solution for injection is also available.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "Contacera is an exciting addition to our NSAID portfolio. Due to the potential clinical advantages of Meloxicam, Contacera gives vets an important additional option for NSAID management. It is a logical fit with the other products in our range and benefits from a choice of presentations."
For further information, contact your Zoetis Account Manager, visit www.zoetis.co.uk, or ring Zoetis' Customer Support: 0845 3008034
References
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
The company says that the effervescent tablet presentation was designed to significantly improve vaccination practices for poultry producers while maintaining reliable virus protection.
Boehringer says this dispensing form reduces the risk of stock solution contamination and, when compared to glass vials, the small blister packs make vaccine management safer for operators, take up less room in the fridge and reduce packaging waste by 90%.
HatchPak IB H120 NeO will be available shortly in packs of 10 tablets of 1000 doses or 10 tablets of 2000 doses.
Callum Blair, Boehringer Ingelheim Avian and Swine Brand Manager, said: "The addition of HatchPak IB H120 NeO to our NeO product portfolio is evidence of our continued investment in the poultry sector."
Duncan makes three requests of the UK Government:
The first is to make changes to encourage more overseas vets, and specifically the return of EU vets.
The second is to increase funding for UK universities to provide veterinary courses.
The final request is to update the regulatory framework to enable veterinary nurses to expand their role.
Full article: https://ivcevidensia.co.uk/News/duncan-phillips-time-to-overhaul-vet-support
Vets4Pets has unveiled its latest national TV advertising campaign, which airs for the first time during Coronation Street on ITV tonight.
The 30-second commercial was shot at five different locations around the UK and features John Davies-Riand MRCVS Vet Partner at Vets4Pets Leeds and Sarah Scott Vet Nurse Partner at Vets4Pets Kettering.
The commercial is running nationally until 28th March and forms part of a national campaign offering owners of elderly pets a discounted £25 senior pet health check with a vet and a half price bag of senior pet food.
Gill Hammond, Head of Brand Marketing said: "It was really important to us when planning this new campaign that we feature our real partners, they are at the end of the day the core of our business and the faces that our clients see when they visit us. The offer itself, focusing on senior pets is testament to our partners' and their teams' commitment to on-going pet health care."
Lee Ashton, founder of Bugler Smith, the agency behind the new ad said: "Working with Vet4Pets on this project has been a really exciting process. Having got under the skin of the brief, and carried out some initial research within Vets4Pets practices nationwide, the overwhelming and consistent theme from everyone we spoke to, was how they have a real passion for pets and making every difference they can.
"This was key to our message, and we felt it was really important to use their best brand ambassadors (their own vets and veterinary nurses) to introduce the brand to the public, to really demonstrate in a straight forward way what makes them different to other vet practices, and we're really pleased with the outcome."
Vikaly is indicated for the nutritional and medical management of chronic kidney disease in adult and senior cats with proteinuria, from IRIS stage 2.
The new diet delivers the same therapeutic dosage as benazepril tablets (0.5–1 mg/kg bodyweight/day).
Nutrition-wise, Vikaly is low phosphorus (0.5% as fed), has reduced protein (30% as fed), contains omega-3 fatty acids (1.2%, including 0.6% EPA & DHA) and offers high metabolisable energy (416 kcal/100g).
Virbac highlights data showing that CKD remains the leading cause of mortality in cats over five years old and affects up to 40% of feline patients over the age of ten1,2.
The company says administering daily treatment is recognised as a major issue for CKD cat owners with 45% of owners not administering treatment daily as they should and 51% of owners citing administration difficulties as the reason why3.
This new product eliminates the need to administer medication separately, which could completely transform treatment compliance, removing the risk of missed doses and reducing stress for both cats and their owners.
Virbac says that due to the pharmacokinetic profile of benazepril, which is incorporated into the kibble, at an equivalent dose Vikaly displays greater ACE inhibition than benazepril tablets4.
The rate of food consumption also does not affect plasma Benazeprilat levels, ensuring consistent treatment efficacy regardless of the cat’s feeding behaviour5.
Virbac says that in practice, this means that even if the cat being treated consumes less than 50% of their daily ration, efficacy is maintained with ACE activity similar to that of benazepril tablets.
Benazepril has a wide therapeutic margin, tolerated to 20x the minimum effective dose (10mg/kg) for 52 weeks, with the first signs of toxicity being reduced erythrocytes counts & ovary/oviduct weights6.
Virbac says that with Vikaly, these levels cannot be reached because the active ingredient is contained in food, which would require a cat to consume more than 10 times their daily ration.
Vikaly is presented in a 1.5kg bag, which equates to a 30 day supply for a 4.5kg cat with normal bodyweight.
It can be fed alongside wet food, providing that the cat consumes at least 50% of their daily ration before being given the wet food.
The daily ration can also be administered in several smaller meals throughout the day, to accommodate the individual preferences of the cat and to promote consistent food intake.
Vikaly is a prescription diet.
The company says Salmoporc has been used on German and Polish farms for over 15 years and has proved to be safe and effective in controlling salmonella.
The vaccine can be administered orally in piglets and via subcutaneous injection in sows.
Company vet Dr Rike Schmelz said: "Salmonella in pigs is growing threat and an important zoonotic disease. According to the 2018 European Food Safety Authority (EFSA) report, salmonellosis is the second most reported zoonosis in Europe with over 90,000 cases reported in humans.
"Salmonella typhimurium and monophasic Salmonella typhimurium represented 17 per cent of confirmed human cases in 2017 so constitutes a major risk to humans."
VetSurgeon.org understands the new vaccine is expected in the UK sometime after October, before which it can be obtained under a Special Import Certificate.
A graduate of University College Dublin, Richard started out in first opinion practice after completing an internship at the University of Glasgow.
While studying medicine, Richard researched mast cell tumours in dogs, which led to an MSc in clinical Oncology. He went on to complete a PhD on mast cell tumours at the Royal Veterinary College in 2008.
Richard works with referral oncology patients and clients two days a week at LVS and currently spends the rest of his working week as an oncology consultant for IDEXX Laboratories.
From February, Richard will also be working at Southfield Veterinary Specialists in Laindon, Essex, thereby allowing him to refer oncology patients for radiation therapy at Southfields when necessary.
Richard said: "Having never been comfortable with operating myself, working with a team of this calibre and experience in a welcoming environment within central London was very attractive. It has been a very fulfilling role for me, especially as both our team and the scope of the services we can offer continue to expand.
"Given the high standard of care offered by local vets in the area, the patients referred to LVS are often very challenging. Together with our clients’ high expectations, the service is definitely not run-of-the-mill but all the more rewarding because of that.
"I’m looking forward to bringing my experience in both research and clinical spheres to LVS."
Richard’s main professional interests are mast cell tumours, novel diagnostics and immunotherapeutics, but he is experienced in all aspects of veterinary oncology and can also offer advice about internal medicine cases.
The team at the centre will be led by Dr Ryk Botes (pictured right), a Medivet Branch Partner with a special interest in orthopaedics and, in particular, replacement surgery.
The company says it is investing in specialist equipment to help the team refine current surgical techniques, including a gait analysis walkway which will be used to help diagnose the cause of lameness and be a means to measure improvement in surgical cases objectively. The data it provides will also enable the team to publish its results in peer-reviewed papers.
Ryk, who qualified in South Africa and joined Medivet in 2013, said: "The volume of elbow, hip and knee replacements we undertake is growing rapidly and the creation of this new centre of excellence at Medivet Faversham will enable us to provide an even higher standard of service to our clients and to help develop and refine orthopaedic techniques for use by the wider veterinary community.
"Data from the gait analysis walkway will be particularly useful in sharing our findings in scientific papers. We will also use the data to support an ongoing research project in elbow replacement surgery in partnership with one of the leaders in implant technology based in Zurich, Switzerland.
For the research, 326 recruited veterinary practices examined 812 cats and 662 dogs using a standardised flea inspection protocol in April and June 2018.
Fleas were collected, the species identified, and pooled flea samples from each host were analysed for the presence of pathogens using PCR and sequence analysis.
Overall, fleas were found on 28.1% of cats and 14.4% of dogs.
Unsurprisingly, over 90% of the fleas on both cats and dogs were our dear old friends, Ctenocephalides felis.
The PCR results found that at least 14% of the samples were positive for at least one pathogen, and 11.3% were positive for Bartonella spp (35 from cats, 4 from dogs), a pathogen which was identified as a risk to veterinary professionals and others with direct animal contact in a 2010 research paper2.
Entomologist Professor Richard Wall from the University of Bristol said: "Fleas are the most clinically important ectoparasites of dogs and cats worldwide.
"Rising levels of pet ownership, climate change and globalisation are increasing the importance of a detailed understanding of the endemicity and prevalence of flea-borne pathogens. This requires continued surveillance to detect change.
"The results have shown the high numbers of cats and dogs that still carry fleas and the relatively high prevalence of Bartonella spp found in the samples provided, which is of significant concern for the health of the pet, pet owner and veterinary practice staff."
Nicola Barclay, Senior Product Manager at MSD Animal Health said: "The Big Flea Project results demonstrate the ongoing need for pet owners to understand the importance of flea prevention, particularly with the implications of infestation for human and animal health.
"It’s particularly important at this time of the year as the weather is getting warmer and infestation is more likely to occur.
"Our national launch today has been designed to raise awareness amongst pet owners and encourage them to seek advice from the veterinary practice.
"Building awareness of the risks of fleas to practices and pet owners is also at the forefront of our ongoing campaign."
According to the company, two promotional videos it prepared for social media have already reached more than 1.7 million people in the first two days of the campaign.
Virbac says that some of the UK's best loved pet influencers will also be promoting the campaign to their followers over the coming week.
What is a pet influencer, anyway? Someone who influences pets? I picture a Barbara-Woodhouse sort of character surrounded by a rapt audience of dogs: "Come on now, dogs, eat Veterinary HPM, it really is properly yummy, and sooo good for you."
I digress.
As part of the campaign pet owners will be able use an online protein calculator to check whether their current pet food is providing optimal levels of protein to their pet.
Pet owners will also be able to locate their nearest veterinary practice stockist using a new locator tool on the Virbac website and benefit from a discount voucher for their first Veterinary HPM purchase, which can only be redeemed in participating veterinary practices.
Tracey West, Nutrition Manager at Virbac, said: "Nutrition plays such a key role in the long-term health and well-being of our pets, and veterinary practices play such a key role in educating pet owners on this important subject.
"We’re delighted that as part of our ‘pro-veterinary’ strategy for Veterinary HPM, we will be able to help drive pet owners back into veterinary practices with this campaign."
For more information, speak to your Virbac Territory Manager.
Outcome of temporary tracheostomy tube-placement following surgery for brachycephalic obstructive airway syndrome in 42 dogs1 was undertaken at Dick White Referrals, UK. A retrospective case series of dogs that had a temporary tracheostomy tube placed in the post-operative period following surgery for BOAS was obtained from the referral hospital.
Of the 42 dogs, 11 had a tracheotomy tube placed electively and 31 had one placed as an emergency. The overall postoperative complication rate in the study was 95%. The minor complication rate – defined as resulting in no observable compromise of the clinical status and/or self-limiting, such as a cough - was 71%. The major complication rate – defined as resulting in discernible harm to the patient, such as cyanosis and dyspnoea - was 83%. 41/42 dogs were classified as having successful tracheostomy tube management.
Marius Stordalen, lead author of the paper said: "Contrary to what had been previously thought, this manuscript shows that in an appropriate clinical setting, temporary tracheostomy tube placement following multi-level airway surgery for brachycephalic obstructive airway syndrome carries a good prognosis for the majority of patients."
Nick Jeffery, editor of JSAP added: "Whilst overall mortality rate was low following placement of a tracheostomy tube in the postoperative period, there was a high overall complication rate. This finding demonstrates the need for continuous monitoring and intensive care for patients following placement of tracheostomy tube.”
The full article can be found in the May issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13127
The session will cover the indications and case selection for surgery, alongside the surgical steps for cholecystectomy and cholecystoduodenostomy.
Alasdair will discuss:
The session is aimed at veterinary surgeons and is intended to help attendees refresh their knowledge and build confidence in dealing with biliary tract surgery in small animals.
The session costs £50.
https://vet-learn.com/product/biliary-mucocoele-and-other-biliary-tract-surgery
The RCVS Disciplinary Committee has dismissed a case against a veterinary surgeon said to have been dishonest in claims made against insurance following a dog's veterinary treatment.
At the end of the four-day hearing, the Committee found Sheena Brimelow, formerly employed by Kinver Veterinary Practice in Kinver, Stourbridge, not guilty of charges relating to seven insurance claims submitted between 1 January 2008 and 1 October 2009. These related to her parent's dog, a Cairn terrier, which she had treated at her then employer's practice. Ms Brimelow admitted that she had submitted invoices with her claims showing the retail prices for several items, when she had paid the practice only the cost prices. She said that she had deleted records from the practice computer showing the retail prices so that the ingoings and outgoings in the practice finances were accurate.
The Committee considered whether Ms Brimelow had either behaved dishonestly or, in the alternative, ought to have known not to have included the sums she did in the insurance claims forms. The Committee found that Ms Brimelow was an honest and reliable witness. She had explained openly what she had done, entirely consistently, from the first time the allegations had been put to her by the practice owner. It noted that an insurance company representative also considered her actions to be "a genuine misunderstanding," although subsequently a complaint was made by the insurance company to the College about Ms Brimelow's actions. The Committee found there were no clear guidelines in the practice as to how staff insurance claims should be handled. It also felt that, as a result of the insurer's communications failures, it was not difficult to believe that Ms Brimelow was unaware of how claims concerning the insured pets of veterinary practice staff members were expected to be handled.
From the evidence presented in the hearing, the Committee calculated that Ms Brimelow had benefited by only £90.50. The Committee noted that she had offered to repay any monies to her employer or the insurer, and that the insurer's loss adjusters had thought this was a matter for Ms Brimelow and her employer. The College had also referred the matter to the police, who said it was not in the public interest to proceed with the matter, a decision they based on the low value of the loss and Ms Brimelow's offer to pay back the money.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "The Committee notes the reasons given by the police for undertaking no criminal investigation in this case, and agrees with that analysis. The Committee must apply the same standard of proof as would have been applied in a criminal case. In all the circumstances, the Committee is far short of being satisfied so that it is sure that Ms Brimelow acted dishonestly in this case."
"The Committee considers that [Ms Brimelow] was naïve and misguided in handling the insurance claims in the way that she did," he continued. "However, the Committee considers there was a lack of proper guidance within the practice as to how staff insurance claims should be handled. In these circumstances the Committee is not sure that the College has proved that the Respondent ought to have known that she should not have included sums on the claims form, which did not represent the costs that she had incurred."
Both elements of the charge were accordingly dismissed.
Although the regulator says the changes should impose only limited administrative costs, VetSurgeon.org estimates that implementation may still run to several thousand pounds for some practices.
Under the reforms, practices will need to:
In total, the CMA package introduces more than a dozen new operational requirements for veterinary practices.
Practices will also have to pay a new levy to the RCVS to fund its expanded role running the price comparison service, estimated at £450-£550 annually, after a £150-£250 setup charge.
Once the Order is made — currently expected in September 2026 — most of the transparency measures will need to be implemented within three months by larger veterinary groups and six months by smaller practices.
More operational changes, such as written estimates, itemised billing and the new prescription rules, follow later, with smaller practices typically given up to 12 months to comply.
The final stage will see practices submitting data to the RCVS for its upgraded Find a Vet comparison platform once the system has been built.
Prescription fees will be capped at £21 for the first medicine prescribed in a consultation and £12.50 for each additional medicine, with both figures rising annually in line with CPI, and practices will need to assess the impact on their business model.
Doxycare is a doxycycline indicated for the treatment of bacterial respiratory tract infections in cats and dogs due to organisms sensitive to doxycycline, and for the treatment of tick-borne Ehrlichia canis infection in dogs. Doxycare is presented in two strengths: 40mg and 200 mg. Both are licensed for use in cats and dogs. The meat-flavoured tablets are scored for quarter splitting to support more accurate dosing.
Metrocare is a metronidazole indicated for the treatment of gastrointestinal tract infections caused by Giardia spp. and Clostridia spp. and the treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria. Metrocare is available in two strengths: 250mg and 500 mg. Both are licensed for use in cats and dogs. The meat-flavoured tablets are scored for quarter splitting.
Cephacare, Animalcare’s first-generation cephalosporin, is now also available in a 1000 mg strength meat-flavoured tablet. Cephacare is licensed to treat skin infections, urinary tract infections, respiratory tract infections, digestive tract infections and infections of the oral cavity. The existing 50 mg strength tablet is licensed for use in cats and dogs. The new 1000 mg size tablets are scored to be halved and licensed for use in larger dogs.
James Beaumont, Product Manager, said: "We aim to offer our customers flexible and convenient solutions for the products they need to use every day in practice, while supporting more accurate and responsible dosing. The additions of Doxycare and Metrocare to our range, together with the new 1000 mg Cephacare strength tablet, mean that we are now able to offer a broader range of antibiotics for use in both cats and dogs."